Baader Bank INC Takes $2.06 Million Position in Bausch Health Companies Inc. (NYSE:BHC)

Baader Bank INC acquired a new stake in shares of Bausch Health Companies Inc. (NYSE:BHCGet Rating) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 90,293 shares of the company’s stock, valued at approximately $2,063,000.

Several other hedge funds have also recently made changes to their positions in BHC. Glassman Wealth Services boosted its position in shares of Bausch Health Companies by 71.4% in the fourth quarter. Glassman Wealth Services now owns 1,152 shares of the company’s stock worth $32,000 after purchasing an additional 480 shares during the period. Aviva PLC boosted its position in shares of Bausch Health Companies by 2.2% in the first quarter. Aviva PLC now owns 45,626 shares of the company’s stock worth $1,044,000 after purchasing an additional 971 shares during the period. Fortis Advisors LLC boosted its position in shares of Bausch Health Companies by 17.3% in the first quarter. Fortis Advisors LLC now owns 6,775 shares of the company’s stock worth $155,000 after purchasing an additional 1,000 shares during the period. Creative Financial Designs Inc. ADV boosted its position in shares of Bausch Health Companies by 525.0% in the first quarter. Creative Financial Designs Inc. ADV now owns 1,250 shares of the company’s stock worth $29,000 after purchasing an additional 1,050 shares during the period. Finally, DekaBank Deutsche Girozentrale boosted its position in shares of Bausch Health Companies by 8.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 15,315 shares of the company’s stock worth $352,000 after purchasing an additional 1,190 shares during the period. 70.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on BHC shares. Truist Financial lowered shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. JPMorgan Chase & Co. lowered shares of Bausch Health Companies from an “overweight” rating to a “neutral” rating in a research report on Thursday, July 28th. Piper Sandler dropped their target price on shares of Bausch Health Companies from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Friday, September 9th. Finally, Royal Bank of Canada upped their target price on shares of Bausch Health Companies from $4.50 to $8.00 and gave the stock a “sector perform” rating in a research report on Thursday, September 1st. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Bausch Health Companies presently has a consensus rating of “Hold” and an average price target of $10.60.

Bausch Health Companies Price Performance

Bausch Health Companies stock opened at $7.36 on Wednesday. The company has a market cap of $2.66 billion, a price-to-earnings ratio of 61.34, a PEG ratio of 0.11 and a beta of 1.21. The firm’s fifty day moving average is $6.78 and its 200 day moving average is $12.93. The company has a quick ratio of 0.87, a current ratio of 1.08 and a debt-to-equity ratio of 85.63. Bausch Health Companies Inc. has a 52-week low of $4.00 and a 52-week high of $29.58.

Bausch Health Companies Company Profile

(Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

Recommended Stories

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.